Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Clinical Trial Information: NCT02415413
| Autores: | , , |
|---|---|
| Tipo de documento: | artigo |
| Data de publicação: | 2024 |
| País: | España |
| Recursos: | Universidad Autónoma de Madrid |
| Repositório: | Biblos-e Archivo. Repositorio Institucional de la UAM |
| Idioma: | inglês |
| OAI Identifier: | oai:dnet:biblosearchi::fc53fecbc677ce07a61e011000d9a077 |
| Acesso em linha: | https://hdl.handle.net/10486/758021 https://dx.doi.org/10.1200/JCO.23.0277 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Antineoplastic Combined Chemotherapy Protocols Consolidation Chemotherapy Dexamethasone Hematopoietic Stem Cell Transplantation Melphalan Multiple Myeloma Oligopeptides Smoldering Multiple Myeloma Transplantation, Autologous Medicina |
| Resumo: | Clinical Trial Information: NCT02415413 |
|---|